e-med-isral-ribbon

Tadalafil Treats Erectile Dysfunction; Low Cardiovascular Risk

Tadalafil (Cialis), a selective phosphodiesterase type 5 inhibitor, treats erectile dysfunction (ED) with little adverse cardiovascular effect, according to new clinical data presented May

25 at the 97th annual meeting of the American Urological Association in Orlando, Florida.

  “Cialis was statistically superior to placebo in enabling men with ED to have successful intercourse at 24 or 36 hours after taking the drug and showed a consistent effect at both time points,” author Raymond Rosen, PhD, from Robert Wood Johnson Medical School in Piscataway, NJ, says in a news release.

 “The duration of effectiveness did not appear to influence the incidence or severity of side effects.” In a phase III, randomized, clinical study, 348 men with mild-to-severe ED received tadalafil 20 mg or placebo over an 8-week period.

Patients were instructed to attempt intercourse on 2 occasions at 24 hours after dosing and on 2 occasions at 36 hours after dosing. Tadalafil was statistically superior to placebo in the percentage of successful sexual intercourse attempts at 24 and 36 hours (P<.001), as well as in secondary outcome measures including penetration ability, satisfaction with hardness of erection, and overall satisfaction (P<.001). Treatment-related adverse effects reported by more than 5% of patients were headache, flushing, and dyspepsia. Less than 2% of patients in either group left the study because of adverse effects, and there were no treatment-related serious adverse events reported.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ אי-מד שיווק רפואי בע”מ
 כל הזכויות שמורות
09-765-8233 

 

הנך גולש/ת באתר כאורח/ת.

במידה והנך מנוי את/ה מוזמן/ת לבצע כניסה מזוהה וליהנות מגישה לכל התכנים המיועדים למנויים
עדיין לא מנוי/ה ונמנה/ת על הצוות הרפואי? מוזמן/ת לבצע הרשמה כאן
להרשמה לאתר
להמשך גלישה כאורח סגור חלון זה